Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Abstract P066: Gain and loss of function genome-wide CRISPR screens identify Hippo signalling as an important driver of resistance in EGFR mutant lung cancer

Matthias Pfeifer, Jonathan Brammeld, Stacey Price, Matthew Martin, Hannah Thorpe, Aurelie Bornot, Ercia Banks, Nin Guan, Shanade Dunn, Maria Lisa Guerriero, Daniel O'Neill, James Pilling, Davide Gianni, James Brownell, Paul Smith, Ultan McDermott

Mol Cancer Ther (2021) 20 (12_Supplement): P066.

https://doi.org/10.1158/1535-7163.TARG-21-P066

Published: 01 December 2021

View articletitled, Abstract P066: Gain and loss of function genome-wide CRISPR screens identify Hippo signalling as an important driver of resistance in EGFR mutant lung cancer

Journal Articles

Abstract A170: Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

Meghana M. Kulkarni, Jon Winter, David Whalley, ian Dale, Christopher Denz, Nin Guan, Deepa Bhavsar, Andrew Zhang, Timothy Rasmusson, Adrian Fretland, Sylvie M. Guichard

Mol Cancer Ther (2018) 17 (1_Supplement): A170.

https://doi.org/10.1158/1535-7163.TARG-17-A170

Published: 01 January 2018

View articletitled, Abstract A170: Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

Journal Articles

Abstract B172: Identification of a novel RNA processing mechanism of intronic readthrough to a transcriptional stop leading to truncated transcript expression, including FANCI and ATM, upon CDK12 inhibition

Christopher Denz, Jeffrey Johannes, Yi Yao, Meghana Kulkarni, Austin Dulak, Nin Guan, Nancy Su, Michelle Lamb, Stephen Fawell, Sylvie Guichard

Mol Cancer Ther (2018) 17 (1_Supplement): B172.

https://doi.org/10.1158/1535-7163.TARG-17-B172

Published: 01 January 2018

View articletitled, Abstract B172: Identification of a novel RNA processing mechanism of intronic readthrough to a transcriptional stop leading to truncated transcript expression, including FANCI and ATM, upon CDK12 inhibition

Journal Articles

Tumors with AKT1^E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D'Cruz, Michael Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, Emma L. Jenkins

Mol Cancer Ther (2015) 14 (11): 2441–2451.

https://doi.org/10.1158/1535-7163.MCT-15-0230

Published: 03 November 2015

View articletitled, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Includes: Supplementary data

Journal Articles

Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Nin Guan, Oona Delpuech, Danielle Greenawalt, Kelly Jacques, Farzin Gharahdaghi, Michael Zinda, Paul J. Smith, Sylvie M. Guichard

Mol Cancer Ther (2013) 12 (11_Supplement): C144.

https://doi.org/10.1158/1535-7163.TARG-13-C144

Published: 01 November 2013

View articletitled, Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Journal Articles

Abstract C274: FGF receptor mutations and fusions are therapeutic targets for inhibition by AZD4547.

Christopher R. Denz, Nin Guan, Kelly Jacques, Elaine Kilgour, Emma Jenkins, Sylvie Guichard, Paul Smith

Mol Cancer Ther (2013) 12 (11_Supplement): C274.

https://doi.org/10.1158/1535-7163.TARG-13-C274

Published: 01 November 2013

View articletitled, Abstract C274: FGF receptor mutations and fusions are therapeutic targets for inhibition by AZD4547.

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract P066: Gain and loss of function genome-wide CRISPR screens identify Hippo signalling as an important driver of resistance in EGFR mutant lung cancer

Abstract A170: Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

Abstract B172: Identification of a novel RNA processing mechanism of intronic readthrough to a transcriptional stop leading to truncated transcript expression, including FANCI and ATM, upon CDK12 inhibition

Tumors with AKT1^E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Abstract C274: FGF receptor mutations and fusions are therapeutic targets for inhibition by AZD4547.

Email alerts

AACR Journals

Update search

Abstract P066: Gain and loss of function genome-wide CRISPR screens identify Hippo signalling as an important driver of resistance in EGFR mutant lung cancer

Abstract A170: Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

Abstract B172: Identification of a novel RNA processing mechanism of intronic readthrough to a transcriptional stop leading to truncated transcript expression, including FANCI and ATM, upon CDK12 inhibition

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Abstract C274: FGF receptor mutations and fusions are therapeutic targets for inhibition by AZD4547.

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Tumors with AKT1^E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors